all these are looking ripe for this week
ams ,dcd,hti,rgo,hrd,goal,ubc,and of course smith@nephew,slough estates,hawtins plc,hsbc,3ii,ng,sse,dsg. tips for the week free!!!!!!!!!!!!!!1

Half Yearly Report

Q2 Financial Highlights
· Revenue of $1,029 million, up 2% on an underlying basis
· Trading profit of $234 million, up 6% on an underlying basis
· Trading profit margin up 80 bps to 22.7% as ASD restructuring benefits come through
· Strong performance from Sports Medicine Joint Repair and NPWT
· EPSA consistent at 18.1 cents
· Group moves to net cash of $150 million
· Interim dividend increased 50% to 9.9¢ and new progressive dividend policy

Smith & Nephew completes Healthpoint acquisition

Smith & Nephew plc (LSE: SN, NYSE: SNN), the global medical technology business, today announces the completion of the acquisition of substantially all the assets of Healthpoint Biotherapeutics ("Healthpoint"). The purchase price of $782 million in cash has been financed from Smith & Nephew's existing cash resources and bank facilities.

The acquisition gives Smith & Nephew a strong position in bioactives, the fastest growing area of advanced wound management.

Smith & Nephew said its full year profits to be at the lower end of its guided range after a third quarter where growth was flat outside US and emerging markets but its artificial hips business returned to growth. Revenue grew 3% to $1.15bn in the three months to 30 September, leading management to expect underlying revenue growth for the full year to be at the lower end of the 3-4% guided range, with profit margins to be at the lower end of the guided 20-70 basis points range.